Skeletal muscle

Handbook of Toxicology of Chemical Warfare Agents

Volumn , Issue , 2009, Pages 509-531

  Gupta, Ramesh C ^a   Dettbarn, Wolf D ^b   Milatovic, Dejan ^c  

^a MURRAY STATE UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884459587     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012374484-5.00035-3     Document Type: Chapter

References (135)

1. Abramson J.J., Salama G. Critical sulfhydryls regulate calcium release from sarcoplasmic reticulum. J. Bioenerg. Biomembr. 1989, 21:283-294.
2. Adler M., Hinman D., Hudson C.S. Role of muscle fasciculations in the generation of myopathies in mammalian skeletal muscle. Brain Res. Bull. 1992, 29(2):179-187.
3. Anderson D.E., Yuan X.J., Tseng C.M., et al. Nitrone spin traps block calcium channels and induce pulmonary artery relaxation independent of free radicals. Biochem. Biophys. Res. Commun. 1993, 193:878-885.
4. Anderson R.J. Effect of diisopropylfluorophosphate and soman on rat skeletal muscle contracture during tetanic stimulation. J. Toxicol. Environ. Health 1987, 22:491-496.
5. Ariens A.T., Meeter E., Wolthuis O.L., Benthem R.M.J. Reversible necrosis at the endplate region in striated muscles of the rat poisoned with cholinesterase inhibitors. Experientia 1969, 25:57-59.
6. Bakry N.M., el-Rashidy A.H., Eldefrawi A.T., Eldefrawi M.E. Direct actions of organophosphate anticholinesterases on nicotinic and muscarinic acetylcholine receptors. J. Biochem. Toxicol. 1988, 3:235-259.
7. Barnard E.A., Lai J., Pizzey J. Synaptic and extrasynaptic forms of acetylcholinesterase in skeletal muscles: variation with fiber type and functional considerations. Neuromuscular Diseases 1984, 455-463. Raven Press. G. Serratrice (Ed.).
8. Beraneck R., Vyskocil F. The action of tubocurarine and atropine on the normal and denervated rat diaphragm. J. Physiol. (Lond.) 1967, 188:53-66.
9. Berg D.K., Keyy R.B., Sagent P.B., Williamson P., Hall Z.W. Binding of a-bungarotoxin to acetycholine receptors in mammalian muscle. Proc. Natl Acad. Sci. USA 1972, 69:141-147.
10. Bevan S., Steinbach J.H. The distribution of a-bungarotoxin binding sites on mammalian skeletal muscle developing in vivo. J. Physiol. (Lond.) 1977, 267:195-213.
11. Blottner D., Luck G. Just in time and place: NOS/NO system assembly in neuromuscular junction formation. Microsci. Res. Tech 2001, 55(3):171-180.
12. Bowman W.C. Pharmacology of Neuromuscular Function 1980, University Park Press, Baltimore, pp. 1-186.
13. Braithwaite A.W., Harris A.J. Neural influence on acetylcholine receptor clusters during embryonic development of skeletal muscles. Nature (Lond.) 1979, 279:549-551.
14. Bright J.E., Inns R.H., Tuckwell N.J., Griffiths G.D., Marrs T.C. A histochemical study of changes observed in the mouse diaphragm after organophosphate poisoning. Hum. Exp. Toxicol. 1991, 10:9-14.
15. Brown C.G., Cooper C.E. Nanomolar concentrations of nitric oxide inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase. FEBS Lett. 1994, 356:295-298.
16. Brunelli L., Crow J.P., Beckman J.S. The comparative toxicity of nitric oxide and peroxynitrite to. Escherichia coli. Arch. Biochem. Biophys 1995, 316:327-334.
17. Buccafusco J.J., Graham J.H., Aronstam R.S. Behavioral effects of toxic doses of soman, an organophosphate cholinesterase inhibitor, in the rat: protection afforded by clonidine. Pharmacol. Biochem. Behav 1988, 29:309-319.
18. Carlson C.G., Dettbarn W.-D. A comparison of the effects of acute and chronic cholinesterase inactivation of spontaneous transmitter release. Brain Res. 1983, 264:285-292.
19. Carlson C.G., Dettbarn W.-D. Presynaptic actions of cholinergic agents on organophosphate-treated nerve terminals. Asia Pac. J. Pharmacol 1987, 2:129-139.
20. Carlson C.G., Dettbarn W.-D. The effects of paraoxon and other anticholinesterases on spontaneous quantal transmitter release in the rat. Asia Pac. J. Pharmacol 1988, 3:201-210.
21. Carter A.J. Antagonists of the NMDA receptor-channel complex and motor coordination. Life Sci. 1995, 57:917-929.
22. Chang C.C., Chen T.F., Chuang S.T. Influence of chronic neostigmine treatment on the number of acetylcholine receptors and the release of acetylcholine from the rat diaphragm. J. Physiol 1973, 230:613-618.
23. Clanton T.L., Zuo L., Klawitter P. Oxidants and skeletal muscle function: physiologic and pathophysiologic implications. Proc. Soc. Exp. Biol. Med. 1999, 222:253-262.
24. Clinton M.E., Dettbarn W.-D. Prevention of phospholine-induced myopathy with d-tubocurarine, atropine sulfate, diazepam, and creatine phosphate. J. Toxicol. Environ. Health 1987, 21:435-444.
25. Clinton M.E., Misulis K.E., Dettbarn W.-D. Effects of phenytoin, ketamine, and atropine methyl nitrate in preventing neuromuscular toxicity of acetylcholinesterase inhibitors soman and diisopropylphosphorofluoridate. J. Toxicol. Environ. Health 1988, 24:439-449.
26. Danysz W., Gossel M., Zajaczkowski W., Dill D., Quack G. Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? Case of amantadine and memantine. J. Neurol. Transm. Park. Dis. Dement. Sect. 1994, 7:155-166.
27. DeBleecker J.L. Intermediate syndrome in organphosphate poisoning. Toxicology of Organophosphate and Carbamate Compounds 2006, 371-380. Academic Press, Amsterdam. R.C. Gupta (Ed.).
28. Dettbarn W.-D. Pesticide induced muscle necrosis: mechanisms and prevention. Fundam. Appl. Toxicol. 1984, 4:S18-S26.
29. Dettbarn W.-D., Milatovic D., Zivin M., Gupta R.C. Oxidative stress, acetylcholine, and excitotoxicity. Antioxidants and Free Radicals in Health and Disease 2001, 183-212. Prominent Press, Scottsdale, AZ. J. Marwah, A. Kanthasamy (Eds.).
30. Fambrough D.M. Control of acetycholine receptors in skeletal muscle. Physiol. Rev. 1979, 59:165-227.
31. Fenichel G.M., Kibler W.B., Olson W.H., Dettbarn W.-D. Chronic inhibition of cholinesterase as a cause of myopathy. Neurology 1972, 22:1026-1033.
32. Frandsen U., Lopez-Figueroa M., Hellsten Y. Localization of nitric oxide synthase in human skeletal muscle. Biochem. Biophys. Res. Commun 1996, 227:88-93.
33. Giulivi C. Functional implications of nitric oxide produced by mitochondria in mitochondrial metabolism. Biochem. J 1998, 332:673-679.
34. Gollinick P.D., Betrocci L.A., Kelso T.B., Wih E.H., et al. The effect of high intensity exercise on the respiratory capacity of skeletal muscle. Pflügers Arch. 1990, 415:407-413.
35. Grossmann W., Jurna I. Die wirkung von memantin auf die membranen sensibler nervenfaserbündel. Arzneim. Forsch. Drug Res. 1977, 27:1483-1487.
36. Grosswald, D.E., Dettbarn, W-D. (1983a). Characterization of acetylcholinesterase molecular forms in slow and fast muscle of rats. Neurochem. Res. 8: 983-95.
37. Grosswald, D.E., Dettbarn, W-D. (1983b). Nerve crush induced changes in molecular forms of AChE in soleus and extensor digitorum muscles. Exp. Neurol. 79: 519-31.
38. Grozdanovic Z., Nakos G., Dahrmann G., et al. Species-independent expression of nitric oxide synthase in the sarcolemma region of visceral and somatic striated muscle fibers. Cell Tissue Res. 1995, 281:493-499.
39. 14C] valine into protein in the development of tolerance to diisopropylphosphorofluoridate (DFP) toxicity. Toxicol. Appl. Pharmacol 1986, 84:551-560.
40. Gupta R.C., Dettbarn W.-D. Alterations of high-energy phosphate compounds in the skeletal muscles of rats intoxicated with diisopropylphosphorofluoridate (DFP) and soman. Fundam. Appl. Toxicol 1987, 8:400-407.
41. Gupta R.C., Dettbarn W.-D. Potential of memantine, d-tubocurarine and atropine in preventing acute toxic myopathy induced by organophosphate nerve agents: soman, sarin, tabun and VX. NeuroToxicology 1992, 13:500-514.
42. Gupta R.C., Goad J.T. Role of high-energy phosphates and their metabolites in protection of carbofuran-induced biochemical changes in diaphragm muscle by memantine. Arch. Toxicol 2000, 74:13-20.
43. Gupta R.C., Patterson G.T., Dettbarn W.-D. Mechanisms involved in the development of tolerance to DFP toxicity. Fundam. Appl. Toxicol 1985, 5:17-28.
44. Gupta R.C., Patterson G.T., Dettbarn W.-D. Mechanisms of toxicity and tolerance to diisopropylphosphorofluoridate at the neuromuscular junction of the rat. Toxicol. Appl. Pharmacol. 1986, 84:541-550.
45. Gupta, R.C., Patterson, G.T., Dettbarn, W-D. (1987a). Biochemical and histochemical alterations following acute soman intoxication in the rat. Toxicol. Appl. Pharmacol. 87: 393-402.
46. Gupta, R.C., Patterson, G.T., Dettbarn, W-D. (1987b). Acute tabun toxicity: biochemical and histochemical consequences in brain and skeletal muscles of rat. Toxicology46: 329-41.
47. Gupta R.C., Misulis K.E., Dettbarn W.-D. Activity dependent characteristics of fast and slow muscle: biochemical and histochemical considerations. Neurochem. Res. 1989, 14:647-655.
48. Gupta R.C., Patterson G.T., Dettbarn W.-D. Comparison of cholinergic and neuromuscular toxicity following acute exposure to sarin and VX in rat. Fundam. Appl. Toxicol 1991, 16:449-458.
49. Gupta R.C., Goad J.T., Kadel W.L. Cholinergic and noncholinergic changes in skeletal muscles by carbofuran and methyl parathion. J. Toxicol. Environ. Health 1994, 43:291-304.
50. Gupta, R.C., Milatovic, D., Zivin, M., Dettbarn, W-D. (2000a). Seizure-induced changes in energy metabolites and effects of N-tert-butyl-alpha-phenylnitrone (PBN) and vitamin E in rats. Eur. J. Physiol. 440: R160-2.
51. Gupta, R.C., Goad, J.T., Milatovic, D., Dettbarn, W-D. (2000b). Cholinergic and noncholinergic brain biomarkers of insecticide exposure and effects. Hum. Exp. Toxicol. 19: 297-308.
52. Gupta, R.C., Milatovic, D., Dettbarn, W-D. (2001a). Depletion of energy metabolites following acetylcholinesterase inhibitor-induced status epilepticus: protection by antioxidants. NeuroToxicology22: 271-82.
53. Gupta, R.C., Milatovic, D., Dettbarn, W-D. (2001b). Nitric oxide modulates high-energy phosphates in brain regions of rats intoxicated with diisopropylphosphorofluoridate or carbofuran: prevention by N-tert-butyl-alpha-phenylnitrone or vitamin E. Arch. Toxicol. 75: 346-56.
54. Gupta R.C., Milatovic D., Dettbarn W.-D. Involvement of nitric oxide in myotoxicity produced by diisopropylphosphorofluoridate (DFP)-induced muscle hyperactivity. Arch. Toxicol 2002, 76:715-726.
55. Hall Z.E. Multiple forms of acetylcholinesterase and their distribution in endplate and nonendplate regions of rat diaphragm muscle. J. Neurobiol. 1973, 4:343-361.
56. Hudson C.S., Ras J.E., Tiedt T.N., Albuquerque E.X. Neostigmine-induced alterations at the mammalian neuromuscular junction. II. Ultrastructure. J. Pharmacol Exp. Ther. 1978, 205:340-356.
57. Huie R.E., Padmaja S. The reaction of NO with superoxide. Free Rad. Res. Commun 1993, 18:195-199.
58. Inns R.H., Tuckwell N.J., Bright J.E., Marrs T.C. Histochemical demonstration of calcium accumulation in muscle fibers after experimental organophosphate poisoning. Hum. Exp. Toxicol 1990, 9:245-250.
59. Jovanovic D. The effect of bis-pyridinium oximes on neuromuscular blockade induced by highly toxic organophosphates in rat. Arch. Int. Pharmacodyn 1983, 262:231-241.
60. Karalliedde L., Henry J.A. Effects of organophosphates on skeletal muscle. Hum. Exp. Toxicol 1993, 12:289-296.
61. Karlin A. The Cell Surface and Neuronal Function 1980, 191-260. Elsevier/North-Holland Biomedical, Amsterdam. C.W. Cotman, G. Poste, G.L. Nicolson (Eds.).
62. Katz B., Miledi R. The effect of atropine on acetylcholine action at the neuromuscular junction. Proc. R. Soc. Lond. B 1973, 184:221-226.
63. Kawabuchi M., Osame M., Watanabe S., Igata A., Kanaseki T. Myopathic changes at the end-plate region induced by neostigmine methylsulfate. Experientia (Basel) 1976, 32:623-625.
64. Kloog Y., Rehavi M., Maayani S., Sokolovsky M. Anticholinesterase and antiacetylcholine activity of 1-phencyclohexylamine derivatives. Eur. J. Pharmacol 1977, 45:221-227.
65. Kobzik L., Reid M.B., Bredt D.S., Stamler J.S. Nitric oxide in skeletal muscle. Nature 1994, 372:546-548.
66. Koelle G.B., Gilman A. Anticholinesterase drugs. J. Pharmacol. Exp. Ther 1949, 95:166-216.
67. Koyuncouglu H., Kara I., Gunel M., et al. N-methyl-D-aspartate antagonists, glutamate release inhibitors, 4-aminopyridine at neuromuscular transmission. Pharmacol. Res. 1998, 37:1-7.
68. Laskowski M.B., Dettbarn W.-D. The pharmacology of experimental myopathies. Annu. Rev. Pharmacol. Toxicol 1971, 17:387-409.
69. Laskowski M.B., Olson W.H., Dettbarn W.-D. Ultrastructural changes at the motor endplate produced by an irreversible cholinesterase inhibitor. Exp. Neurol 1975, 47:290-306.
70. Laskowski M.B., Olson W.H., Dettbarn W.-D. Initial ultrastructural abnormalities at the motor endplate produced by a cholinesterase inhibition. Exp. Neurol 1977, 57:13-33.
71. Leonard J.P., Salpeter M.M. Agonist-induced myopathy at the neuromuscular junction is mediated by calcium. J. Cell Biol. 1979, 82:811-819.
72. Leonard J.P., Salpeter M.M. Calcium-mediated myopathy at neuromuscular junctions of normal and dystrophic muscle. Exp. Neurol 1982, 76:121-138.
73. Lipp J.A. Effect of diazepam upon soman-induced seizure activity and convulsions. Electroenceph. Clin. Neurophysiol 1972, 32:557-560.
74. Lonnerholm G., Widerlov E. Effect of intravenous atropine and methyl atropine on heart rate and secretion of saliva in man. Eur. J. Clin. Pharmacol 1975, 8:233-240.
75. MacDonald R.L., McLean M.J. Anticonvulsant drugs: mechanisms of action. Adv. Neurol 1986, 44:713-736.
76. Malick J.B., Barnett A. Central versus peripheral anticholinergic activity as assessed by two in vivo procedures in mice. J. Pharm. Sci. 1975, 64:1066-1068.
77. Marwaha, J. (1980a). Some mechanisms underlying actions of ketamine on electromechanical coupling in skeletal muscle. J. Neurosci. Res.5: 43-50.
78. Marwaha, J. (1980b). Electrophysiological studies of the action of ketamine in frog skeletal muscle. Neuropharmacology19: 765-72.
79. Massoulie J., Bon S. The molecular forms of cholinesterase and acetylcholinesterase in vertebrates. Annu. Rev. Neurosci 1982, 5:57-106.
80. Masuo K., Enomoto K.-I., Maeno T. Effects of memantine on the frog neuromuscular junction. Eur. J. Pharmacol 1986, 130:187-195.
81. Menking D.E., Thompson R.G., WolffV.L., Valdes J.J. Irreversible organophosphate effects on nicotinic acetylcholine receptor/ion channel complex. Def. Techn. Inf. Cent. Rep 1990.
82. McLean M.J., MacDonald R.L. Limitation of sustained high frequency repetitive firing: a common anticonvulsant mechanisms of action. Neurotransmitters, Seizures and Epilepsy III 1986, 23-41. Raven Press, New York. G. Nistico, P.L. Morselli, K.G. Lloyd, A.G. Fariello, J. Engel (Eds.).
83. McLean M.J., Gupta R.C., Dettbarn W.-D., Wamil A.W. Prophylactic and therapeutic efficacy of memantine against seizures produced by soman in the rat. Toxicol. Appl. Pharmacol. 1992, 112:95-103.
84. Meshul C.K., Boyne A.F., Deshpande S.S., Albuquerque E.X. Comparison of the ultrastructural myopathy induced by anticholinesterase agents at the end plates of rat soleus and extensor muscles. Exp. Neurol 1985, 89:96-114.
85. Milatovic, D., Radic, Z., Zivin, M., Dettbarn, W-D. (2000a). Atypical effect of some spin trapping agents: reversible inhibition of acetylcholinesterase. Free Radic. Biol. Med. 28: 597-603.
86. Milatovic, D., Zivin, M., Hustedt, E., Dettbarn, W-D. (2000b). Spin trapping agent phenyl-N-tert-butylnitrone prevents diisopropylphosphorofluoridate-induced excitotoxicity in skeletal muscle of the rat. Neurosci. Lett. 278: 25-8.
87. Milatovic D., Zivin M., Gupta R.C., Dettbarn W.-D. Alterations in cytochrome c oxidase activity and energy metabolites in response to kainic acid-induced status epilepticus. Brain Res. 2001, 912:67-78.
88. Mishina M., Takai T., Imito K., Noda M., Takahashi T., Numa S., Methfessel C., Sakmann B. Molecular distinction between fetal and adult forms of muscle acetylcholine receptor. Nature 1986, 321:406-411.
89. Misulis K.E., Clinton M.E., Dettbarn W.-D., Gupta R.C. Differences in central and peripheral neural actions between soman and diisopropylfluorophosphate, organophosphorus inhibitors of acetylcholinesterase. Toxicol. Appl. Pharmacol 1987, 89:391-398.
90. 2-isoprostanes) in carbon tetrachloride hepatotoxicity. J. Clin. Invest 1992, 90:2502-2507.
91. Müntener M., Zenker W. Fiber type and non-endplate acetylcholinesterase in normal and experimentally altered muscles. Anat. Embryol 1986, 173:377-383.
92. Narayan M., Wright V.P., Berliner L.J., et al. Do nitric oxide and peroxynitrite contribute to hydroxylation reactions in fatigued diaphragm?. FASEB J 1997, 11:A72.
93. Noble M.D., Peacook J.H., Hofmann W.W. Prednisone-neostigmine interactions at cholingergic junctions. Muscle Nerve 1979, 2:155-157.
94. Parsons C.G., Danysz W., Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist -a review of preclinical data. Neuropharmacology 1999, 30:735-767.
95. Patterson G.T., Gupta R.C., Dettbarn W.-D. Diversity of molecular form patterns of acetylcholinesterase in skeletal muscle of rat. Asia Pac. J. Pharmacol 1987, 2:265-273.
96. Patterson G.T., Gupta R.C., Misulis K.E., Dettbarn W.-D. Prevention of diisopropylphosphorofluoridate (DFP)-induced skeletal muscle fiber sections in rat. Toxicology 1988, 48:237-244.
97. Paul N., Mannathukkaran T.J. Intermediate syndrome following carbamate poisoning. Clin. Toxicol 2005, 43:867-868.
98. Pazos A.J., Green E.J., Busto R., McCabe P.M., Baena R.C., Ginsburg M.D., Globus M.Y., Schneiderman N., Dietrich W.D. Effects of combined postischemic hypothermia and delayed N-tert-butyl-a-phenylnitrone (PBN) administration on histopathological and behavioral deficits associated with transient global ischemia in rats. Brain Res. 1999, 846:186-195.
99. Radic Z., Taylor P. Structure and function of cholinesterases. Toxicology of Organophosphate and Carbamate Compounds 2006, 161-186. Academic Press, Amsterdam. R.C. Gupta (Ed.).
100. Reid M.B., Kobzik L., Bredt D.S., Stamler J.S. Nitric oxide modulates excitation-contraction coupling in the diaphragm. Comp. Biochem. Physiol. A Mol. Integ. Physiol. 1998, 119(1):211-218.
101. Roberts D.V., ThesleffS. Acetylcholine release from motor-nerve endings in rats treated with neostigmine. Eur. J. Pharmacol. 1969, 6:281-285.
102. Roberts, L.J., Morrow, J.D. (2000). Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free Radic. Biol. Med. 28: 505-13.
103. Salpeter M.M., Kasprzak H., Feng H., Fentuck H. Endplates after esterase inactivation in vivo: correlation between esterase concentration, functional response, and fine structure. J. Neurocytol 1979, 8:95-115.
104. Salpeter M.M., Leonard J.P., Kasprzak H. Agonist-induced postsynaptic myopathy. Neurosci. Comment 1982, 1:73-83.
105. Senanayake N., Karalliedde L. Neurotoxic effects of organophosphorus insecticides: an intermediate syndrome. N. Engl. J. Med 1987, 316:761-763.
106. Schmidt H.H., Lohmann S.M., Walter U. The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochim. Biophys. Acta 1993, 1178:153-175.
107. Silvango F., Xia H., Bredt D.S. Neural nitric oxide synthase: an alternatively spliced isoform expressed in differentiated skeletal muscle. J. Biol. Chem. 1996, 271:11204-11208.
108. Sjodin B., Westing Y.H., Apple F.S. Biochemical mechanisms for oxygen free radical formation during exercise. Sport Med 1990, 10:236-254.
109. Sket D., Brzin M., Vreca I. Effect of HI-6 and diazepam on the increase of creatine kinase isoenzymes activity in plasma of atropinized, soman-poisoned rats. Acta Pharm, Jugoslav 1989, 39:151-159.
110. Sket, D., Dettbarn, W-D., Clinton, M.E., Sketelj, J., Cucek, D., Brzin, M. (1991a). Prevention of diisopropylphosphorofluoridate-induced myopathy by botulinum toxin type A blockage of quantal release of acetylcholine. Acta Neuropathol. 82: 134-42.
111. Sket, D., Dettbarn, W-D., Clinton, M.E., Sketelj, D. et al. (1991b). Prevention of diisopropylphosphorofluoridate (DFP)-induced skeletal muscle fiber lesions in rat. Toxicology48: 237-44.
112. Smith L.W., Smith J.D., Criswell D.S. Involvement of nitric oxide synthase in skeletal muscle adaptation to chronic overload. J. Appl. Physiol 2002, 92:2005-2011.
113. Sohal G.S., Boydston W.R. Influence of neostigmine treatment on embryonic development of acetylcholine receptors and neuromuscular junction. J. Cell. Biol. 1982, 94:540-548.
114. Soussi B., Idstrom J.P., Schersten T., Bylund-Fellenius A.C. Kinetic parameters of cytochrome c oxidase in rat skeletal muscle: effect of endurance training. Acta Physiol. Scand 1989, 135:373-379.
115. Stamler J.S., Meissner G. Physiology of nitric oxide in skeletal muscle. Physiol. Rev. 2001, 81:209-237.
116. Sterri S.H., Lyngas S., Fonnum F. Toxicity of soman after repetitive injection of sublethal doses in guinea pig and mouse. Acta Pharmacol. Toxicol 1981, 49:8-13.
117. Tattersall J.E. Effects of organophosphores anticholinesterases on nicotinic ion channels at adult mouse muscle endplates. Br. J. Pharmacol. 1990, 101:349-357.
118. Tattersall J.E.H. The acetylcholine receptor: effects of organophosphorus compounds and oximes. Hum. Exp. Toxicol 1992, 11:559-560.
119. Taylor P. Anticholinesterase agents. Goodman and Gilman's The Pharmacological Basis of Therapeutics 2006, 201-216. McGraw-Hill, New York. 11th edition. L.L. Brunton, J.S. Lazo, K.L. Parker (Eds.).
120. Waerhaug O., Ottersen O.P. Demonstration of glutamate-like immunoreactivity of rat neuromuscular junctions by quantitative electron microscopic immunocytochemistry. Anat. Embryol. 1993, 188:501-513.
121. Wand P., Sontag K.-H., Cremer H. Effects of 1,3-dimethyl-5-aminoadamantane hydrochloride (DMAA) on the stretch-induced reflex tension of flexor muscles and the excitability of the 8-loop in decerebrate and spinal cats. Arzneim. Forsch. Drug Res. 1977, 27(11):8-12.
122. Wang M.X., Murrell D.F., Szabo C., et al. Nitric oxide in skeletal muscle: inhibition of nitric oxide synthase inhibits walking speed in rats. Nitric Oxide: Biol. Chem. 2001, 5:219-232.
123. Wecker L., Dettbarn W.-D. Paraoxon-induced myopathy: muscle specificity and acetylcholine involvement. Exp. Neurol 1976, 51:281-291.
124. Wecker L., Stouse M. Effects of chronic paraoxon administration on skeletal muscle fiber integrity. Res. Comm. Pathol. Pharmacol 1985, 49:203-213.
125. Wecker, L., Kiauta, T., Dettbarn, W-D. (1978a). Relationship between acetylcholinesterase inhibition and the development of a myopathy. J. Pharmacol. Exp. Ther. 206: 97-104.
126. Wecker, L., Laskowski, M.B., Dettbarn, W-D. (1978b). Neuromuscular dysfunction induced by acetylcholinesterase inhibition. Fed. Proc. 37: 2818-22.
127. Wesemann V.W., Ekenna O. Effect of 1-aminoadamantanes on the MAO activity in brain, liver, and kidney of the rat. Arzheim. Forsch. Drug Res. 1982, 32:1241-1243.
128. Wesemann V.W., Sontag K.H., Maj J. Pharmacodynamics and pharmacokinetics des memantine. Arzneim. Forsch. Drug Res. 1983, 33:1122-1134.
129. Wessler, I., Karl, M., Mai, M., Dilner, A. (1987a). Muscarinic receptors on the rat phrenic nerve evidence for positive and negative feedback mechanisms. Naunyn-Schmiedebergs Arch. Pharmacol.335: 605-12.
130. Wessler, I., Rasbach, J., Scheuer, B., Hillen, U., Kilbinger, M. (1987b). Effects of d-tubocurarine on [3H]acetylcholine release from the rat phrenic nerve at different stimulation frequencies and train lengths. Naunyn-Schmiedebergs Arch. Pharmacol. 335: 496-501.
131. Yaari Y., Selzer M.E., Pincus J.H. Phenytoin: mechanisms of its anticonvulsant action. Ann. Neurol 1986, 20:171-184.
132. Yang Z.P., Dettbarn W.-D. Diisopropylphosphorofluoridate-induced cholinergic hyperactivity and lipid peroxidation. Toxicol. Appl. Pharmacol 1996, 138:48-53.
133. Yang Z.P., Dettbarn W.-D. Lipid peroxidation and changes of cytochrome c oxidase and xanthine oxidase in organophosphorus anticholinesterase-induced myopathy. J. Physiol. (Paris) 1998, 92:157-161.
134. Younkin S.G., Rosenstein C., Collins P.L., Rosenberry T.L. Cellular localization of the molecular forms of acetylcholinesterase in rat diaphragm. J. Biol. Chem. 1982, 257:13630-13637.
135. Zivin M., Milatovic D., Dettbarn W.-D. The effects of status epilepticus on cytochrome c oxidase activity in the rat brain. FASEB J. A1102 1999.